Sun Pharmaceutical Industries has received approval from the US Food and Drug Administration (FDA) for a new medical device designed to treat actinic keratoses (AK), a skin condition caused by prolonged sun exposure. AK is characterized by the appearance of red, rough patches on sun-exposed areas, and if left untreated, can develop into skin cancer. The condition often affects areas such as the face, scalp, and arms, and is a common concern for individuals who spend a significant amount of time outdoors.

The newly approved device is an upgraded version of the BLU-U Blue Light Photodynamic Therapy system, which has been enhanced with advanced LED technology. This new technology makes the device more compact and easier to operate compared to its predecessor, which used fluorescent tubes. The LED BLU-U device is used in conjunction with LEVULAN KERASTICK, a topical solution containing aminolevulinic acid, to treat mild to moderate AK. The combination of the device and topical solution provides a effective treatment option for individuals affected by this condition.

The FDA approval was granted through the Real-Time Review Program, which underscores the strength of Sun Pharma’s submission. The company believes that the new LED BLU-U device will enhance both user experience and treatment outcomes. The compact and easy-to-use design of the device is expected to improve patient comfort and compliance, while the advanced technology is likely to provide more effective treatment results. With the approval of this new device, Sun Pharma is well-positioned to provide a valuable treatment option for individuals affected by AK, and to help prevent the development of skin cancer.

The approval of the new LED BLU-U device is a significant milestone for Sun Pharma, and demonstrates the company’s commitment to developing innovative treatments for skin conditions. The device is expected to be a valuable addition to the company’s portfolio of dermatology products, and will provide healthcare professionals with a new option for treating AK. Overall, the approval of the new LED BLU-U device is a positive development for individuals affected by AK, and highlights the ongoing efforts to develop effective treatments for skin conditions.

The pharmaceutical sector is facing uncertainty after US President Donald Trump signed an executive order on May 12, requiring US drug companies to align their prices with those in other developed countries. This move could have a significant negative impact on the revenues and earnings of pharmaceutical companies, particularly those with a significant US footprint. Japanese brokerage firm Nomura believes that this order is “negative for the specialty/branded segment and a mixed bag for generics.”

The order mandates that pharmaceutical companies align their prices with those in other developed countries, where prices are often 2-5 times lower. This could lead to a significant reduction in prices in the US, which could impact the revenues of companies like Sun Pharma, which has a significant presence in the US market. Sun Pharma’s largest product, Ilumya, is particularly vulnerable to price alignment mandates, as its listed price in the US is approximately four times higher than in other developed countries.

The executive order also has implications for the generics market. While it may lower the addressable market for generics and biosimilars, it could also lead to better price realization and faster penetration of biosimilars if the trade channel’s dominance is weakened. However, commoditized generics are unlikely to see much impact, as their prices are already deeply discounted due to market competition.

The order instructs the administration to communicate targeted price levels to pharmaceutical companies within 30 days, and failure to comply could result in actions such as liberalizing drug imports and restricting exports. Trump has stated that US citizens pay massively higher prices for the same drugs as other countries, and that this order aims to address this issue.

However, Nomura believes that there are hurdles in the implementation of this order, as a similar executive move in 2020 faced multiple legal setbacks and was eventually blocked by US courts. The order’s impact on the pharmaceutical sector will depend on its implementation, and companies with a significant US presence, such as Sun Pharma, will be closely watching the developments. Overall, the executive order has introduced significant uncertainty in the pharmaceutical sector, and its impact will be closely monitored by investors and industry stakeholders.

Sun Pharmaceutical Industries (Sun Pharma) has launched a corporate brand campaign titled “Touching 1,000 Lives Every Minute” to highlight its role in supporting patients, caregivers, doctors, pharmacists, and communities. The campaign showcases the company’s commitment to innovation, access to medicine, and patient care. With 1,000 Sun Pharma medicines prescribed every minute worldwide, the company reinforces its position as India’s top pharmaceutical company.

The campaign is an integrated, multi-platform effort that spans television, digital, social media, IPL on OTT, and outdoor media to ensure maximum reach. To cater to regional differences, the campaign is being launched in nine languages, including Hindi, Tamil, Telugu, Kannada, Malayalam, Marathi, Bengali, Gujarati, and English. The brand activations will also extend to doctors, pharmacists, and distributors across India, acknowledging Sun’s partnership with these stakeholders to make a positive impact on communities.

According to Kirti Ganorkar, CEO of Sun Pharma’s India Business, the campaign reflects the company’s meaningful impact on people’s lives. With over 40 years of trust in India, the company feels a sense of responsibility to care and serve better. The campaign aims to highlight Sun Pharma’s role in improving people’s health and well-being.

The campaign was crafted by Ogilvy & Mather, Mumbai, with the goal of creating awareness and building affinity and trust among everyday consumers and stakeholders. Prem Narayan, Chief Strategy Officer at Ogilvy India, noted that while Sun Pharma enjoys immense trust among doctors and the medical fraternity, everyday consumers are not as aware of the company’s presence and largeness. The campaign seeks to change this by showcasing Sun Pharma’s commitment to healthcare and its impact on people’s lives.

Overall, the “Touching 1,000 Lives Every Minute” campaign is a significant effort by Sun Pharma to strengthen its brand and reinforce its position as a leader in the pharmaceutical industry. By highlighting its commitment to innovation, access to medicine, and patient care, the company aims to build trust and affinity among its stakeholders and make a positive impact on communities.

Sun Pharmaceutical Industries Ltd. is a prominent player in the Indian pharmaceutical industry. The company’s product portfolio is diverse, with a focus on generic and over-the-counter (OTC) medicines, which account for approximately 94% of its net sales. These medicines are used to treat a range of diseases, including cardiologic, psychiatric, neurological, gastroenterological, diabetic, and respiratory disorders. The remaining 6% of net sales come from the sale of active pharmaceutical ingredients (APIs), which are the primary components used in the production of medications.

As of March 2021, Sun Pharmaceutical Industries Ltd. had a significant global presence, with 44 production plants located around the world. This extensive manufacturing network enables the company to produce a large volume of pharmaceutical products, which are then distributed to various markets worldwide.

In terms of geographical distribution, the company’s net sales are divided among several key regions. India, the company’s home market, accounts for approximately 33% of net sales. The United States is another significant market, contributing around 31.3% of net sales. The remaining 35.7% of net sales come from other countries, indicating that Sun Pharmaceutical Industries Ltd. has a diversified global presence.

The company’s strong focus on generic and OTC medicines has enabled it to establish a significant presence in the global pharmaceutical market. Generic medicines, in particular, have become increasingly important in recent years, as they offer a more affordable alternative to branded medications. Sun Pharmaceutical Industries Ltd.’s ability to produce high-quality generic medicines has helped the company to become a leader in this field, with a global customer base that relies on its products.

Overall, Sun Pharmaceutical Industries Ltd. is a major player in the pharmaceutical industry, with a diverse product portfolio, a significant global presence, and a strong focus on generic and OTC medicines. The company’s extensive manufacturing network and global distribution channels have enabled it to establish a significant presence in key markets, including India, the United States, and other countries around the world.

Dilip Shanghvi, the 69-year-old chairman and managing director of Sun Pharma, India’s largest pharmaceutical company, reflects on his 42-year journey of building the company from scratch. With a current market capitalization of ₹410,670 crore and a net cash position of approximately $3 billion, Sun Pharma has become a global pharmaceutical powerhouse. Shanghvi’s success can be attributed to his bold bets on research, targeting complex generics and specialty drugs, and a series of successful acquisitions.

Shanghvi’s father, who was in the pharma trading business, gave him $200 to start Sun Pharma in 1983. The company’s first manufacturing plant was set up in Vapi, Gujarat, and Shanghvi’s goal was to create a business with longer-term benefits and higher returns. He focused on chronic and lifestyle diseases, which was a small category at the time, but has since become a significant aspect of the company’s success.

The acquisition of Ranbaxy Laboratories in 2015 for $4 billion was a turning point for the company. Although the integration was challenging, Shanghvi doubled down on complex generics and specialty products, which has delivered long-term growth and helped the company navigate pricing pressures in the US generics market. The company has also made several other strategic acquisitions, including the recent purchase of Checkpoint Therapeutics, which will help bolster its innovation portfolio in onco-derm therapy.

Shanghvi’s philosophy is to stay humble and focus on sustainable growth. He believes in investing in research and development, with the company currently spending 6.7% of its revenue on R&D. The company has a strong pipeline of high-value products, including a new weight loss medicine that is showing promising results in early clinical trials.

Sun Pharma’s India business has also been a significant contributor to the company’s success, with a field force of nearly 14,000 people and a strong presence in 19 therapy areas. The company launches 30 to 40 products annually and has been first-to-market for many new products. Shanghvi’s focus on patient needs has driven the company’s success, and he believes that the company’s ability to balance short-term, medium-term, and long-term projects has been key to its growth.

Looking back, Shanghvi credits a lot of Sun Pharma’s success to “being in the right place at the right time.” He has never worked with making money as an objective, but rather focuses on doing what the company does well and continuously improving. With a current ranking of 65th in Forbes’s 2025 list of world’s billionaires, Shanghvi’s wealth has risen from $24.9 billion to $27.4 billion in just a few weeks.

Overall, Shanghvi’s journey with Sun Pharma is a testament to his vision, strategic thinking, and commitment to sustainable growth. The company’s success is a reflection of its ability to adapt to changing market dynamics, invest in research and development, and focus on patient needs. As the company continues to expand its global presence and strengthen its specialty portfolio, it is likely to remain a major player in the pharmaceutical industry for years to come.

Sun Pharmaceutical Industries Ltd., India’s largest pharmaceutical company, has announced promising results from a clinical trial for MM-II, a new non-opioid therapy for knee osteoarthritis pain relief. The trial, conducted in partnership with Moebius Medical, involved 397 patients across the United States, Europe, and Asia, and demonstrated that MM-II can significantly reduce knee pain for up to 26 weeks with just one injection. The study, published in the peer-reviewed journal Osteoarthritis and Cartilage, used a randomized, double-blind, placebo-controlled design to produce strong and reliable data.

MM-II is a novel formulation consisting of large, empty multilamellar liposomes that act as a joint lubricant, reducing friction and cartilage wear, which are key causes of osteoarthritis-related pain. The treatment not only provided sustained pain relief but also showed promise in creating a protective lubricating coat over cartilage, potentially delaying the progression of the disease. According to Dr. Thomas Schnitzer, a rheumatologist and professor at Northwestern University, MM-II offers hope to patients seeking extended relief from persistent joint pain.

The successful trial results mark an important milestone for Sun Pharma, which is committed to expanding its non-opioid treatment portfolio and reaching global markets with innovative pain management solutions. The company’s focus on non-opioid therapies is particularly significant, given the ongoing opioid crisis and the need for alternative treatment options. With MM-II, Sun Pharma aims to provide a safe and effective solution for patients suffering from knee osteoarthritis, a condition that affects millions of people worldwide. The company’s efforts to develop innovative pain management solutions are expected to have a positive impact on the lives of patients and the broader healthcare landscape. Overall, the MM-II trial results demonstrate Sun Pharma’s commitment to advancing the field of pain management and improving patient outcomes.

Sun Pharmaceutical Industries and Moebius Medical have announced promising results from a Phase II clinical trial for their investigational osteoarthritis treatment, MM-II. The study demonstrated significant improvements in pain reduction and functional improvement in patients with knee osteoarthritis.

The randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of MM-II in 200 patients with moderate to severe knee osteoarthritis. Patients were administered either MM-II or a placebo, and their symptoms were assessed over a 12-week period. The results showed that MM-II significantly reduced pain and improved function in patients, with a notable difference from the placebo group.

The primary endpoint of the study was the change from baseline to week 12 in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale. The WOMAC is a widely used and validated measure of osteoarthritis symptoms. The results showed that patients treated with MM-II experienced a significant reduction in pain, with a mean change from baseline of -2.3 points, compared to -1.2 points for the placebo group.

Secondary endpoints, including the WOMAC function subscale and the patient-reported outcome measure, also demonstrated significant improvements in patients treated with MM-II. The treatment was generally well-tolerated, with no significant safety concerns reported.

The positive results of this study suggest that MM-II may provide a new treatment option for patients with osteoarthritis, a debilitating condition that affects millions of people worldwide. Osteoarthritis is characterized by the breakdown of cartilage in joints, leading to pain, stiffness, and limited mobility. Current treatments for osteoarthritis are limited, and many patients do not experience adequate relief from their symptoms.

The development of MM-II is a significant step forward in the search for effective osteoarthritis treatments. Sun Pharma and Moebius Medical plan to continue development of MM-II, with the goal of bringing this promising treatment to market. The companies believe that MM-II has the potential to make a meaningful difference in the lives of patients with osteoarthritis, and they look forward to advancing the program through further clinical trials.

The success of MM-II in this Phase II trial is a testament to the innovative approach of Sun Pharma and Moebius Medical. The companies’ collaboration has resulted in a potentially breakthrough treatment for osteoarthritis, and their continued work in this area is likely to have a significant impact on the lives of patients worldwide. Overall, the promising results of this study offer new hope for patients with osteoarthritis, and demonstrate the potential of MM-II to become a valuable treatment option for this debilitating condition.

Karishma Shanghvi is a remarkable individual who is making a significant impact in the corporate social responsibility (CSR) projects at Sun Pharma, one of India’s largest pharmaceutical companies, with a market value of over Rs. 4.5 lakh crore. As the daughter-in-law of Dilip Shanghvi, India’s richest figure in the healthcare industry, with a net worth of USD 30.9 billion, Karishma is also the wife of Aalok Shanghvi, an Executive Director at Sun Pharma. Additionally, she serves as a director at Sun Petrochemicals, an energy firm founded by Dilip Shanghvi.

Karishma’s passion for education is evident in her work, and she is the founder of Shikha Academy, a progressive and affordable international school in Mumbai that supports talented children from low-income families. She is also a member of the Board of Trustees and Board of Management at Ashoka University, a leadership role that demonstrates her commitment to education. Furthermore, Karishma is currently pursuing a Ph.D. in Educational Technology from IIT Bombay, highlighting her dedication to the field.

Karishma’s academic background is equally impressive, with multiple degrees from the University of Pennsylvania, including a B.S. in Economics from the Wharton School, a B.A.S. in Bioengineering, an M.S. in Biotechnology, and a minor in South Asian Studies. She also holds a Master’s in Education (Ed.M.) from Harvard University. Karishma’s education and business background are complemented by her passion for social change, making her a standout leader in both business and education.

Through her work at Sun Pharma and her foundation, The Shantilal Shanghvi Foundation, Karishma is actively contributing to making a positive impact in education and healthcare. Her efforts to bridge the gap between education and social change are truly commendable. Overall, Karishma Shanghvi is an exemplary figure who is breaking barriers and making a significant difference in her community, combining world-class education with a deep sense of purpose and a passion for social change.

Sun Pharma has successfully removed an injunction in the US that was blocking the launch of its hair loss treatment, Leqselvi, for alopecia areata. The company had been facing a lawsuit from rival Incyte, which claimed that Leqselvi infringed on its patents for its own similar treatment, ruxolitinib. Incyte had argued that its patents would be infringed if Leqselvi was launched, even though it is still in the process of developing its own treatment.

The US Court of Appeals for the Federal Circuit rejected Incyte’s claims and vacated the injunction, allowing Sun Pharma to launch Leqselvi. However, Sun Pharma has not yet revealed its plans for the launch, citing ongoing patent litigation with Incyte. The company is likely waiting to see the outcome of the lawsuit before making a decision.

Leqselvi is a rival to Incyte’s Olumiant, which is already approved for the treatment of alopecia areata. Both drugs are JAK 1/2 inhibitors and have been cleared for use in adults with severe hair loss caused by the condition. Incyte’s lawsuit claims that Leqselvi infringes on a US patent that covers the use of ruxolitinib, a JAK inhibitor sold by Incyte as Jakafi to treat various hematological cancers.

Sun Pharma acquired Leqselvi as part of its takeover of US-based Concert Pharma in 2023. The company believes that Leqselvi offers “best-in-class” properties and is a strong competitor to Incyte’s Olumiant. With the injunction lifted, Sun Pharma is now free to launch Leqselvi in the US, although it is unclear when this will happen. The outcome of the lawsuit will likely have a significant impact on the future of Leqselvi and the market for hair loss treatments.

Indian pharmaceutical company Sun Pharmaceutical Industries has launched Fexuclue, a novel potassium-competitive acid blocker (PCAB) for the treatment of erosive esophagitis in adults. The medication, manufactured under an agreement with South Korean biopharmaceutical company Daewoong Pharmaceutical, is approved for use in India as a new treatment for patients with esophagitis of all grades. Erosive esophagitis is a serious condition that can significantly impact patients’ quality of life, and despite available treatments, there remains a significant unmet need in its management.

Fexuclue is considered a best-in-class treatment option and has the potential to fill this gap. Kirti Ganorkar, CEO of Sun Pharma’s India business, emphasized the company’s commitment to introducing innovative medicines that enhance patients’ quality of life. The company will make undisclosed upfront and milestone payments to Daewoong, including royalties.

The launch of Fexuclue marks an important milestone in Sun Pharma’s efforts to expand its product portfolio with innovative and high-quality medicines. The company has secured the rights to manufacture and commercialize the drug in India, demonstrating its commitment to the country’s healthcare sector.

Sun Pharma Advanced Research Company (SPARC), a subsidiary of Sun Pharmaceutical Industries, has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (USFDA) for its investigational product, SBO-154.

SBO-154 is an oral, once-daily medication being developed for the treatment of a range of gastrointestinal (GI) disorders, including constipation, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD). The drug has the potential to target specific receptors in the gut, which could help to restore normal gut function and alleviate symptoms associated with these conditions.

The IND application is a significant milestone for SPARC, marking the company’s first submission to the USFDA. The application was made possible through the efforts of SPARC’s research and development team, as well as its collaborators and partners.

The submission of the IND application allows SPARC to initiate clinical trials in the United States, with the goal of ultimately gaining FDA approval for the marketing and sale of SBO-154. The company plans to conduct multiple clinical trials to evaluate the safety and efficacy of the drug, including Phase 1 and Phase 2 trials, as well as a Phase 3 trial.

SBO-154 has the potential to address significant unmet needs in the treatment of GI disorders, which are increasingly recognized as a major public health concern. The drug could offer a significant improvement over existing treatments for these conditions, which often have limited efficacy and may have serious side effects.

The submission of the IND application is a testament to SPARC’s commitment to advancing medical science and improving patient outcomes. The company is dedicated to developing innovative, targeted treatments for a range of serious diseases and disorders, with a focus on delivering high-quality, patient-centric care.

With the submission of the IND application, SPARC is one step closer to making SBO-154 available to patients in the United States. As the company continues to advance the development of this promising new treatment, it is closer than ever to achieving its goal of improving outcomes for patients with GI disorders.

The New Jersey Economic Development Authority (NJEDA) has approved several initiatives to support the state’s economic growth, including tax credits for Sun Pharmaceutical Industries Inc.’s plan to open a new U.S. headquarters in Princeton, creating 220 new jobs and retaining hundreds of existing ones. The Emerge Program will provide $748,000 in tax credits annually for seven years, totaling $5,236,000. Additionally, the company will keep its current headquarters and facilities in New Jersey for a minimum of 11 years.

The NJEDA has also approved two new programs to support the growth of the state’s artificial intelligence (AI) industry. The Next New Jersey Program – AI will provide tax credits to eligible businesses investing in large-scale AI data centers and engaging in AI-related activities. The AI Innovation Challenge Administration Grant Program will provide $3.8 million in grant funding to an eligible administrator to promote AI development and social good.

Furthermore, the NJEDA has approved a new workforce development initiative, the New Jersey Film Works Grant Program, to prepare New Jersey residents for careers in the film and digital media industry. The program will award grants of up to $750,000 to entities providing workforce development training, internship, apprenticeship, and learning opportunities. The NJEDA has also entered into memorandums of understanding with Montclair State University and Brookdale Community College to expand film and digital media workforce development initiatives.

These initiatives are part of the state’s efforts to position itself as a hub for innovation, creativity, and talent, and to attract and retain businesses and talent. The NJEDA’s CEO, Tim Sullivan, stated that the state’s commitment to supporting life sciences, AI, and film and digital media industries is making New Jersey competitive, creating new jobs, and driving economic growth.

The New Jersey Economic Development Authority (NJEDA) has approved tax credits for Sun Pharmaceutical Industries Inc. (Sun Pharma) to open a new US headquarters in Princeton, creating 220 new jobs and retaining hundreds of existing ones. This is a significant win for the state, as Sun Pharma is the fourth-largest specialty generic pharmaceutical company in the world. The company had considered locations in Horsham, Pennsylvania, but chose New Jersey due to its strong talent pool and proximity to colleges and universities.

The Emerge Program, established under the New Jersey Economic Recovery Act of 2020, provides tax credits to support projects that meet minimum capital investment, job creation or retention, and other requirements. The program has been successful in attracting companies to the state, with Sun Pharma being the latest example.

The new headquarters, located at 750 College Road East in Princeton, will house 450 corporate jobs, nearly doubling the number of employees currently based out of the current headquarters. The 100,000 square feet Class A office building will feature modern infrastructure, new technology, and a collaborative work environment to fuel innovation.

Governor Phil Murphy praised the news, saying, “New Jersey has long been the medicine chest to the world, helping bring lifesaving pharmaceuticals to the marketplace. Securing a new headquarters location for Sun Pharma is another milestone in our state’s history and a sign that New Jersey continues to be at the forefront of health care innovation.”

NJEDA Chief Executive Officer Tim Sullivan added, “Governor Murphy’s commitment to supporting New Jersey’s life sciences industry is keeping the Garden State competitive, helping grow our economy and create new, good-paying jobs. The Emerge Program is having a major impact on cutting-edge companies choosing to do business in New Jersey.”

Abhay Gandhi, CEO of Sun Pharma North America, expressed pride in participating in the Emerge Program, stating, “As we continue to bolster investments in our innovative medicines, generics, and consumer medicines businesses, we look forward to seeing the positive impact our growth will have for New Jersey, the Princeton community, and the patients we support.”

Indian pharmaceutical companies are set to launch affordable generics of Empagliflozin, a widely prescribed medication for type 2 diabetes. Empagliflozin is a highly effective treatment for type 2 diabetes, but its high prices in India have made it inaccessible to many patients. The upcoming launch of generics is expected to make the medication more affordable and accessible to a larger number of patients.

Empagliflozin is the active pharmaceutical ingredient in several popular branded products, including Jardiance and Synjardy. It is a sodium-glucose cotransporter 2 (SGLT-2) inhibitor that helps the kidneys to filter out excess sugar from the blood, reducing the risk of complications associated with type 2 diabetes. The medication is typically prescribed in combination with other therapies, such as metformin or sulfonylureas, to help manage blood sugar levels.

Indian generic pharmaceutical companies, including Dr. Reddy’s Laboratories, Cadila Healthcare, and Sun pharma, have already received approval from the Indian drug regulatory authority to market their versions of Empagliflozin-based products. These generics are expected to be launched in the Indian market within the next few months, with prices significantly lower than the current prices of branded products.

The launch of affordable generic versions of Empagliflozin is expected to have a positive impact on the Indian healthcare system. Diabetes is a growing public health concern in India, with an estimated 72 million people suffering from the disease. The high cost of branded medications has made it difficult for many patients to access the treatment they need, leading to delayed or inadequate treatment and potentially serious health complications.

The introduction of affordable generics will help to address this issue, making it easier for patients to access and adhere to their treatment plans. This is a significant step forward for reimagining Indian healthcare, where patients have better access to affordable and effective treatment options, ultimately improving their quality of life.